All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the Lymphoma Coalition.
The lym Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the lym Hub cannot guarantee the accuracy of translated content. The lym and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The Lymphoma & CLL Hub is an independent medical education platform, sponsored by AbbVie, BeOne Medicines, Johnson & Johnson, Roche, and Sobi, and supported through educational grants from Bristol Myers Squibb, Incyte, Lilly, and Pfizer. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View lym content recommended for you
Satellite Symposium | Treatment options for a patient with ibrutinib-resistant CLL
Featured:
Francesc BoschThe virtual Lymphoma Hub Satellite Symposium, at the 16th International Conference on Malignant Lymphoma (16-ICML), saw a panel of international experts come together to discuss the sequencing of therapies in high-risk relapsed/refractory lymphoma and chronic lymphocytic leukemia (CLL). Professor Francesc Bosch, Vall d'Hebron Barcelona Hospital Campus, Barcelona, ES, discusses treatment options for a patient with ibrutinib-resistant CLL.
Treatment options for a patient with ibrutinib-resistant CLL
Bosch presents his treatment approach to a double-refractory ibrutinib-resistant patient case by firstly discussing the significance of predictive markers and how to use these to discern between different treatments. He then moves on to outline the therapeutic options for this case, including alternative BTK inhibitors, PI3 kinase inhibitors, and CAR T-cell therapy.
Please indicate your level of agreement with the following statements:
The content was clear and easy to understand
The content addressed the learning objectives
The content was relevant to my practice
I will change my clinical practice as a result of this content
Your opinion matters
Which of the following would most increase your confidence in referring patients with R/R large B-cell lymphoma for CAR T-cell therapy?